Principal Investigator

Guy Sauvageau

Molecular Genetics of Stem Cells

Hematologist at Maisonneuve-Rosemont Hospital, Dr. Guy Sauvageau is the founding Investigator of IRIC. After graduating from medical school, he earned a Master’s in Immunology-Virology from the Université de Montréal and a Ph.D. in Experimental Medicine from the University of British Columbia while a member of Keith Humphries’ laboratory.

He founded his own laboratory in 1996 at the Montreal Clinical Research Institute and joined IRIC in 2003. He served as Scientific Director of IRIC from 2003 to 2013 and as CEO from 2007 to 2014. He is the leader of the Leucegene Project, an initiative that brings together several Quebec Investigators for the purpose of improving the characterization of acute myeloid leukemia and developing new therapies for the disease. He is also the Scientific Founder and CEO of ExCellThera, a biotechnology company that develops new methods for the culture of blood stem cells for therapeutic purposes.

Principal Investigator, Molecular Genetics of Stem Cells Research Unit, IRIC

Professor, Department of Medicine, Faculty of Medicine, Université de Montréal

Hematologist, Stem Cell Transplant Centre, Department of Hematology, Maisonneuve-Rosemont Hospital

Scientific Advisor, Quebec Leukemia Cell Bank

Scientific Founder and CEO, ExCellThera

Research unit on molecular genetics of stem cells

Pavillon Marcelle-Coutu, 1343-1355 (1371)

Phone (office)
(514) 343-6111, ext. 7134
Fax
(514) 343-5839
Email
guy.sauvageau@umontreal.ca
Apply for a M.Sc. or a Ph.D.

Molecular Genetics of Stem Cells

The research work carried out in the Sauvageau lab focuses on the study of hematopoietic stem cells (HSCs) and acute myeloid leukemia (AML).

Discover the research unit View the research team

Research topics

Publications

  • January 1, 2023

    Impact of Implementing a Bendamustine-Based Conditioning Regimen on Outcomes of Autologous Stem Cell Transplantation in Lymphoma while Novel Cellular Therapies Emerge.

    Lachance S, Bourguignon A, Boisjoly JA, Bouchard P, Ahmad I, Bambace N, Bernard L, Cohen S, Delisle JS, Fleury I, Kiss T, Mollica L, Roy DC, Sauvageau G, Veilleux O, Zehr J, Chagnon M, Roy J
    Transplant Cell Ther 2023-01-01 ;29( 1 ):34.e1-34.e7

  • January 1, 2023

    Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD.

    Claveau JS, LeBlanc R, Ahmad I, Delisle JS, Cohen S, Kiss T, Bambace NM, Bernard L, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J
    Transplant Cell Ther 2023-01-01 ;29( 1 ):44.e1-44.e9

  • September 13, 2022

    Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia.

    Lisi V, Blanchard E, Vladovsky M, Audemard E, Ferghaly A, Lemieux S, Hébert J, Sauvageau G, Lavallée VP
    Blood Adv 2022-09-13 ;6( 17 ):5160-5164

  • August 23, 2022

    HMGA2 expression defines a subset of human AML with immature transcriptional signature and vulnerability to G2/M inhibition.

    Moison C, Spinella JF, Chagraoui J, Lavallée VP, Lehnertz B, Thiollier C, Boivin I, Mayotte N, MacRae T, Marinier A, Hébert J, Sauvageau G
    Blood Adv 2022-08-23 ;6( 16 ):4793-4806

  • August 22, 2022

    Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.

    Kadri Y, Phan M, Bambace N, Bernard L, Cohen S, Delisle JS, Kiss T, Lachance S, Roy DC, Sauvageau G, Veilleux O, Roy J, Ahmad I
    Curr Oncol 2022-08-22 ;29( 8 ):5955-5962

  • July 1, 2022

    UM171 Expansion of Cord Blood Improves Donor Availability and HLA Matching For All Patients, Including Minorities.

    Dumont-Lagacé M, Feghaly A, Meunier MC, Finney M, Van't Hof W, Masson Frenet E, Sauvageau G, Cohen S
    Transplant Cell Ther 2022-07-01 ;28( 7 ):410.e1-410.e5

  • July 1, 2022

    Hyaluronic acid-GPRC5C signalling promotes dormancy in haematopoietic stem cells.

    Zhang YW, Mess J, Aizarani N, Mishra P, Johnson C, Romero-Mulero MC, Rettkowski J, Schönberger K, Obier N, Jäcklein K, Woessner NM, Lalioti ME, Velasco-Hernandez T, Sikora K, Wäsch R, Lehnertz B, Sauvageau G, Manke T, Menendez P, Walter SG, Minguet S, Laurenti E, Günther S, Grün D, Cabezas-Wallscheid N
    Nat Cell Biol 2022-07-01 ;24( 7 ):1038-1048

  • June 28, 2022

    CEACAM1 is a novel culture-compatible surface marker of expanded long-term reconstituting hematopoietic stem cells.

    Ansari U, Tomellini E, Chagraoui J, Lehnertz B, Mayotte N, Bordeleau ME, Roux PP, Sauvageau G
    Blood Adv 2022-06-28 ;6( 12 ):3626-3631

  • May 19, 2022

    Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.

    Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M
    Nat Commun 2022-05-19 ;13( 1 ):2801

  • March 7, 2022

    CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.

    He L, Arnold C, Thoma J, Rohde C, Kholmatov M, Garg S, Hsiao CC, Viol L, Zhang K, Sun R, Schmidt C, Janssen M, MacRae T, Huber K, Thiede C, Hébert J, Sauvageau G, Spratte J, Fluhr H, Aust G, Müller-Tidow C, Niehrs C, Pereira G, Hamann J, Tanaka M, Zaugg JB, Pabst C
    EMBO Mol Med 2022-03-07 ;e14990

  • See all publications

News

  • February 4, 2022

    Four IRIC researchers receive Canadian Institutes of Health Research grants

    In the Fall 2021 competition, four IRIC research teams were awarded prestigious grants.

  • April 21, 2021

    Talk from Guy Sauvageau at the CCMM

    Leveraging innovation and collaboration to accelerate scientific discoveries in oncology

  • January 12, 2021

    UM171: the molecule that keeps on giving

    In a study published in Cell Stem Cell, a research team of 15 scientists led by UdeM hematologist Guy Sauvageau demonstrates the cancer-fighting molecule’s mechanism of action.

  • November 4, 2019

    Blood cancers: a “new generation” stem cell transplant significantly reduces complications for patients

    In a Phase One-Two clinical trial, the great majority of patients with blood cancers are on the road to recovery, thanks to the UM171 molecule, discovered at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal.

  • July 8, 2019

    Treatment of leukemia: IRIC Investigators publish in Cancer Cell

    Researchers at UdeM have discovered a molecular process implicated in the action of anti-leukemia drugs, opening new avenues for the development of effective treatments for this disease.

  • September 11, 2018

    Dr. Guy Sauvageau elected to the Academy of Science of the Royal Society of Canada

    Dr. Guy Sauvageau, Principal Investigator at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal and hematologist at the Maisonneuve-Rosemont

  • April 25, 2018

    Guy Sauvageau and Josée Hébert, winners of the 2017 Genome Canada “Genomics and Precision Health” competition

    IRIC is proud to announce the $12.8 million in funding awarded to the “Interrogating and implementing Omics for precision medicine in acute myeloid leukemia” project led by Guy Sauvageau and Josée Hébert.

  • March 16, 2015

    World breakthrough by IRIC team of Dr. Guy Sauvageau voted Québec Science Discovery of the Year

    The team of Dr. Guy Sauvageau made an unprecedented breakthrough thanks to the discovery of a new molecule that expands stem cells from umbilical cord blood.

  • See all news

Awards and distinctions

  • Fellow of the Royal Society of Canada, 2018

  • McCulloch Price, International Society for Stem Cell Research, 2016

  • Léo-Pariseau Award, Association francophone pour le savoir, 2015

  • Radio-Canada’s and La Presse Scientist of the Year, 2014

  • Till and McCulloch Award, Stem Cell Network of Canada, 2009

  • Member of Canadian Academy of Health Sciences, 2008

  • Stohlman Scholar Award, Leukemia Lymphoma Society, 2007

  • Till and McCulloch Award, International Society of Hematology, 2006

    • See all awards